CVC  Sanofi Ventures

     Office Locations:

50 Binney Street
Cambridge, MA 02142
Phone: 617-252-7500
Fax: 617-252-7600



  • Early



  • Life Sciences & Healthcare
  • Medical Device



    Sanofi Ventures is the corporate venture capital arm of Sanofi. Previously known as Sanofi-Genzyme BioVentures, the firm offers its portfolio companies access to Sanofi's established expertise and capabilities in science, preclinical and clinical development, regulatory, manufacturing, market access, commercialization, and more. Sanofi invests in early-stage companies developing transformative technologies and products that are considered too early for business development. Sanofi Ventures invests directly in private early-stage biotech and digital health companies with transformative new products and technologies that align with Sanofi's strategy. Current core areas of strategic interest include: rare diseases; vaccines; breakthrough therapies in other core areas of interest: immunology, neurology, oncology, diabetes, and cardio vascular disease; and digital health.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Bernard Davitian VP, Managing Director
    Christopher Gagliardi Director of Investments
    Jason Hafler Senior Director of Investments
    Ruchita Sinha Sr. Director of Investments and Principal


    Recent Funding Events (trailing 12 months):







      Kymera Therapeutics



      Series B


      Evidation Health



      Series C


    Portfolio companies include:

      Common Sensing
        web link

        web link

      Edimer Pharmaceuticals
        web link

      Esperance Pharmaceuticals
        web link

      Evidation Health
        web link

      Expansion Therapeutics
        web link

      Fate Therapeutics
        web link

        web link

      Immune Design
        web link

        web link

      Inozyme Pharma

      Kahr Medical
        web link

      Kymera Therapeutics
        web link

        web link

      Navitor Pharmaceuticals
        web link


      Omada Health
        web link

      Ovid Therapeutics
        web link

      Proteostasis Therapeutics
        web link

      Science 37
        web link

        web link

        web link

      Valerion Therapeutics
        web link

      Yumanity Therapeutics
        web link


    Recent News: